Our portfolio Archive - Arecor

Significantly de-risked product portfolio and pipeline with proven safety and efficacy profiles
AT278 has best-in-class profile compared to the best, gold-standard insulins currently available
Oral peptide delivery platform leverages our formulation and product development expertise, aiming to unlock the challenges of effective oral delivery and to significantly improve bioavailability

Diabetes

AT278 – a disruptor insulin designed to transform Automated Insulin Delivery (AID) systems with the aim of improving patient care for people living with diabetes, by reducing patient burden and improving outcomes
- The only ultra-concentrated (500U/mL) and ultra-rapid-acting insulin in development
- Unique profile, the only insulin that can enable AID use for high insulin users and drive the next generation of miniaturised, longer wear AID systems
- Best-in-class profile compared to the best insulins available to patients today
- Co-development agreement with Sequel Med Tech for preparatory work for Phase 2 clinical trial of AT278 in their AID system
LEARN MORE
Oral delivery of peptides
- Initial focus on developing a novel oral delivery platform, using a GLP-1 receptor agonist (semaglutide) with improved bioavailability compared to current marketed products
- Significant opportunity in developing enhanced oral GLP-1 and additional peptide therapies – currently over 800 peptides are in development, but almost all are injectables
- Current approved oral GLP-1 Rybelsus^® achieves less than 1% bioavailability
- Potential to generate significant value in fast growing obesity and cardiometabolic disease markets
- Proof of success with oral GLP-1 opens up access to potential multi-billion dollar market for the oral delivery of peptides
LEARN MORE